Prevention of infectious complications in rheumatic disease patients: Immunization, Pneumocystis carinii prophylaxis, and screening for latent infections

Current Opinion in Rheumatology

Volumn 11, Issue 3, 1999, Pages 173-178

  Singer, Nora G ^a,c   McCune, W Joseph ^b  

^a Ctr Adv Res Hum Repro I   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Division of Pediatric Otolaryngology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

HUMAN; IMMUNIZATION; INFECTIOUS COMPLICATION; INFLUENZA; INFLUENZA VACCINATION; MEDICAL LITERATURE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

BACTERIAL INFECTIONS; HUMANS; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; PNEUMONIA, PNEUMOCYSTIS; RHEUMATIC DISEASES; VIRUS DISEASES; VIRUS LATENCY;

EID: 0032999714     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199905000-00004     Document Type: Review

References (21)

1. 1 Centers for Disease Control and Prevention: Prevention of Pneumococcal Disease: recommendations of the Advisory Committee on Immunization Practices. MMWR CDC Surveill Summ 1997, 46(RR-8):1-24. Centers for Disease Control and Prevention summary of the latest Advisory Committee on Immunization Practices recommendations for use of pneumococcal polysaccharide vaccine. This article contains information about vaccine effectiveness, indications for vaccination, guidelines for revaccination and the development of pneumococcal conjugate vaccines.
2. 2 Centers for Disease Control and Prevention: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR CDC Surveill Summ 1998, 46(RR-6):1-26. Update on information about controlling influenza during the 1998-1999 flu season. A description of the strains included in the 1998-1999 flu vaccine, influenza-related hospitalizations, and the possible relationship between flu vaccine and Guillain-Barré syndrome are included.
3. 3 Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson D, McBean AM, et al.: Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997, 278:1333-1339. A cost analysis of patients over 65 showing that in groups aged 65 to 74 years, 75 to 84 years, and 85 or more years improves health and saves medical costs.
4. 4 Centers for Disease Control and Prevention: Pneumococcal and influenza vaccination levels among adults aged ≥ 65 years, 1995. MMWR Morb Mortal Wkly Rep 1997, 46:914-919. Estimation and report of increased rates of pneumococcal and influenza vaccination rates for persons 65 years or more based on the 1995 Behavorial Risk Surveillance System.
5. 5 Poland G, Couch R, Faggett W, Nichol K, Sisk J and the National Coalition for Adult Immunization: Improving Influenza and Pneumococcal Immunization Rates Among High-Risk Adults: Summary of a roundtable hosted by the National Coalition for Adult Immunization. 1998:1-26. Summary of roundtable of national experts and participants from volunteer organizations who convened to identify barriers to immunization of high-risk patients and devise strategies to overcome such barriers.
6. 6 Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al.: The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995, 333:889-893.
7. 7 Committee on Infectious Diseases American Academy of Pediatrics Poliovaccination Infections: Polio vaccination infections. In 1997 Red Book: Report of the Committee on Infectious Diseases, edn 24. Edited by Peter G, Hall CB, Halsey NA, Marcy SM, Pickering LK. Elk Grove, IL; 1997:424-433. Summary and rationale for current recommendations from the American Academy of Pediatrics about polio virus immunization.
8. 8 Committee on Infectious Diseases American Academy of Pediatrics Immunization in Special Circumstances: Immunization in special circumstances. In 1997 Red Book: Report of the Committee on Infectious Diseases, edn 24. Edited by Peter G, Hall CB, Halsey NA, Marcy SM, Pickering LK. Elk Grove, IL; 1997:48-71. Summary and rationale for current recommendations from the American Academy of Pediatrics about active and passive immunizations of special patient populations, including, but not limited to, pregnant women, immunodeficient and immunosuppressed children, and asplenic children.
9. 9 Committee on Infectious Diseases American Academy of Pediatrics: HIV infection. In 1997 Red Book: Report of the Committee on Infectious Diseases, edn 24. Edited by Peter G, Hall CB, Halsey NA, Marcy SM, Pickering LK. Elk Grove, IL; 1997:279-304. Summary and rationale for current recommendations from the American Academy of Pediatrics about immunization of HIV-infected children.
10. 10 Committee on Infectious Diseases American Academy of Pediatrics: Varicella-Zoster infections. In 1997 Red Book: Report of the Committee on Infectious Diseases, edn 24. Edited by Peter G, Hall CB, Halsey NA, Marcy SM, Pickering LK. Elk Grove, IL; 1997:573-585. Summary and rationale for current recommendations from the American Academy of Pediatrics for immunization against and exposures to primary and secondary varicella infection.
11. 11 Brodman R, Gilfillan R, Glass D, Schur PH: Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978, 88:735-740.
12. 12 Ristow SC, Douglas G, Condemi JJ: Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978, 88:786-789.
13. 13 Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al.: Clinical and antibody responses after influenza in systemic lupus erythematosus. Ann Intern Med 1978, 88:790-792.
14. 14 Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al.: Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998, 41:1828-1834. A total of 73 SLE patients immunized with pneumococcal, TT, and Haemophilus influenzae type B vaccines had no increase in SLE flare and had significant serologic evidence of response to vaccination. The data supports that such immunization recommended by the Centers for Disease Control and Prevention and American College of Physicians is safe in SLE patients and is likely to be effective.
15. 15 Harrison BJ, Thompson W, Pepper L, Ollier WER, Chakravarty K, Barrett EM, et al.: Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP. Br J Rheumatol 1997, 36:366-369. A comparison of the frequency of immunization 6 weeks before disease onset among 48 patients with inflammatory polyarthritis and 185 consecutive nonimmunized patients showing that, in most cases, patients with inflammatory polyarthritis cannot be distinguished on the basis of immunization history.
16. 16 Zhang D, Nikkari S, Vainionpaa R, Luukkainen R, Yli-Kerttula U, Toivanen P: Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis. J Rheumatol 1997, 24:1260-1265. Reverse transcription polymerase chain reaction on RNA derived from PBMCs and SF cells of RA patients and control patients with other types of inflammatory arthropathy showed no significant differences among the two groups in the detection of viral genomic RNA.
17. 17 ACP Task Force on Adult Immunization and Infectious Disease Society of America: Guide for Adult Immunization, edn 3. Philadelphia: American College of Physicians; 1994.
18. 18 Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du LTH, et al.: Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 1995, 54:991-994.
19. 19 Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrouse B, Royer I, et al.: A prospective, multi-center, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198. Patients with newly diagnosed WG were treated prospectively with daily oral cyclophosphamide and prednisone, or cyclophosphamide every three weeks and daily prednisone. Treatment responses were similar both groups, but the high morbidity and mortality rates were unexpectedly high in all patients, especially for those who received daily oral cyclophosphamide.
20. 20 Hoffman GS: Treatment of Wegener's granulomatosis: Time to change the standard of care? Arthritis Rheum 1997, 40:2099-2104. Hoffman compares the results of the study conducted by Guillevin et al. [19•• in the same issue of Arthritis and Rheumatism to the National Institutes of Health experience with treating WG patients. He discusses prevention of opportunistic infections and strategies that, if shown to be effective in the treatment of patients with WG, may be expected to reduce the morbidity and mortality of patients with WG.
21. 21 Segel G: Enzymatic defects. In Nelson Textbook of Pediatrics, edn 15. Edited by Behrman RE, Kliegman RM, Arvin AM. Philadelphia: WB Saunders; 1996:1405-1408.